Cytochrome P450s (CYPs) are membrane-associated heme proteins and hepatic microsomal enzymes, which participate in drug metabolism and detoxification. Among more than 50 human CYPs, an isoform, CYP3A4, is a major enzyme responsible for drug-drug interactions that is concerned in at least 50% of drug metabolism.
Thus, it is important to know the CYP3A4 inhibitory potency of new drug candidates at an early stage of drug discovery. Although many detailed studies about CYP3A4 inhibitory pharmacophores have been published, 3) precise interactions between inhibitors (or substrates) and CYP3A4 have not been defined well. Recently, the crystal structure of CYP2C5 was determined by Williams et al., 4) which is the first structure of a mammalian microsomal CYP. To understand the molecular basis of CYP3A4 inhibition well, a CYP3A4 homology model was constructed, and inhibitors and substrates were docked into the model. In this report we will describe some interesting features of the putative active site of CYP3A4.
Experimental
Homology Modeling The amino acid sequence of CYP3A4 was taken from the ExPASy web site (http://tw.expasy.org/). The amino acid sequence alignment used for the homology modeling was obtained as follows. The amino acid sequences for which 3D structures were available at the time (Pseudomonas-Putida P450 CAM , 5) Pseudomonas-SP P450 TERP , 6) Saccharopolyspora-Erythraea P450 eryF , 7) Fusarium-Oxysporum P450 NOR , 8) Bacillus-Megaterium P450 BM3 , 9, 10) and mammalian CYP2C5 4) ) were aligned according to their 3D structures using the homology module of Insight II (ver. 2000, Accelrys Inc., San Diego, California, U.S.A.). Subsequently, amino acid sequences of human metabolic CYPs were aligned by sequence homology using ClustalW.
11) The combined alignments were manually revised so that insertions and deletions did not get into the portions corresponding to probable secondary structures, as far as possible, and the following four characteristic motifs of CYPs were aligned: WXXXR (where W is tryptophan, R is arginine, and X is any amino acid) in the alpha-helix C, EXXR (where E is glutamate, R is arginine, and X is any amino acid) in the alphahelix K, ZXXPXXZXPXXZ (where P is proline, Z is aromatic amino acid, and X is any amino acid) after the alpha-helix KЈ and FXXGXXXCXG (where F is phenylalanine, G is glycine, C is cysteine, and X is any amino acid) before the alpha-helix L. 12) According to the alignment (Fig. 1 ), a homology model of CYP3A4 was constructed based on the crystal structure of mammalian CYP2C5 (PDB code:1DT6) using the homology module of Insight II. Although the sequence identities between CYP102 (BM3) and CYP3A4 versus CYP2C5 and CYP3A4 are very similar (22%), CYP2C5 was chosen as a template since the mammalian CYP was presumed to be more suitable than a prokaryotic one. Using the Search/Generate-Loops function of Insight II, conformations of the insertion and deletion parts in the alignment were obtained referring to the known 3-D structures. After some manual adjustments to remove large steric hindrances, the whole structure was subjected to energy minimization for 1000 steps with the steepest descent minimizer, and subsequently 5000 steps with the conjugate gradient minimizer, to a maximum gradient of 0.1 kcal/mol Ϫ1 Å Ϫ1 , using the Discover-ESFF force field (ver 980, Accelrys Inc., San Diego, California, U.S.A.). During the minimization procedure, the following conditions were adopted. The dielectric constant was set to 4*r, where r is the distance between two interacting atoms. The force constant of tethering constraints for the backbone of structurally conserved regions (SCRs, asterisks in Fig. 1 ) and heme was set to 40 kcal/Å 2 to prevent a large movement from the initial positions. Docking of Inhibitors Covalent bonding models of imidazole and methylendioxyphenyl were constructed by full energy minimization using the Discover-ESFF force field. Then, the residual parts of ketoconazole (IC 50 value for CYP3A4 Ͻ0.1 mM 13) ) and a methylenedioxyphenyl compound (3,4- [2-(3,4- ) were connected to the imidazole and methylendioxyphenyl structures obtained above, respectively. Using the Search-Compare module of Insight II, the stable binding mode of each compound was explored by systematic bond rotation within the ligand, including some side chains around the ligand, and energy minimization was continued using the Discover-ESFF force field. The condition of the energy minimization is the same as that described in the homology modeling section.
Paclitaxel (an anticancer drug) and losartan (an antihypertensive) were docked into the CYP3A4 model using Gold (ver. 2.0, the Cambridge crystallographic data centre, U.K. 15) ) with the standard default settings. Pharmacophore Docking of Substrates Pharmacophore Dock (Ph4Dock, 16) ) of MOE (ver. 2003.02, Chemical Computing Group: Montreal, Canada) was performed for losartan and typical CYP3A4 substrates (saquinavir, 17) indinavir, 18) quinidine, 19) nifedipine, 20) terfenadine, 21) ritonavir, 22) dexamethasone, 23) verapamil, 24) erythromycin, 25) testosterone, 25) tamoxifen, 26) fentanyl, 27) amiodarone, 28) and colchicine 29) ). A pharmacophore model for CYP3A4 ligands was manually created based on the docking models of ketoconazole and the methylenedioxyphenyl derivative described above (Fig. 5 ). Exclusive volumes were automatically generated with Ph4Dock according to the atomic positions of the CYP3A4 model. Interaction energy (U ele ϩU vdw ; i.e., summation of intermolecular electrostatic and van der Waals energy) was calculated after energy minimization, which was carried out by the MMFF94s force field 30, 31) for substrate molecules and the side chains of the enzyme within 4.5 Å of each substrate.
Results and Discussion
The active-site pocket of the CYP3A4 model is much larger (950 Å 3 ) than the CYP2C5 crystal structure (420 Å   3 ). In addition, the pocket is divided into three parts, a proximal site and two distal sites from the heme. The larger pocket of CYP3A4 is attributed to the existence of an additional pocket (the distal pocket 2 in Fig. 2) , and is consistent with the broad substrate selectivity of CYP3A4. In the CYP3A4 model, the approach to the additional pocket is comprised of Pro110, Ile120, Asp214, Leu373, and Leu479. On the other hand, the larger amino acids of CYP2C5 (Ile102, Phe114, Leu208, Leu363, and Phe473) occlude access to the additional pocket. The positions of the important residues for substrate-binding [32] [33] [34] [35] [36] [37] [38] [39] (Table 1) , which were confirmed by site-directed mutagenesis, were also checked in the CYP3A4 model. Except for two of them (Asn206 and Val376), most of the important residues were formed in the binding pocket (Pro107, Phe108, Ser119, Ile120, Leu210, Leu211, Asp214, Ile301, Phe304, Ala305, Thr309, Ile369, Ala370, Leu373, Ser478, and Leu479; Fig. 3a) . The Ramachandran plot analyzed by the program Prockeck 40) to check the stereochemical quality, indicates that 99% of non-Gly and non-Pro residues exist in the allowed regions (Fig. 3b) . Although the sequence identity between CYP3A4 and CYP2C5 is only 22%, the above result indicates the validity of the model. Ketoconazole, which was bound in the proximal and the distal site 2, has a length similar to that of the putative binding pocket (ca. 18 Å, Fig. 4a ). On the other hand, the BOC substituent of the methylenedioxyphenyl derivative was docked in the first distal site (distal site 1), and this molecule used all the three sites for binding (Fig. 4b) . The conformations of docked ketoconazole and the methylendioxyphenyl derivative had very similar length in the active-site pocket of the CYP3A4 model. The results are consistent with the facts that shorter and longer analogs of ketoconazole (e.g. fluconazole and itraconazole, respectively) are weaker inhibitors of CYP3A4 41) and shorter analogs of the methylenedioxyphenyl derivative show lower activity for CYP3A4.
14) The accordance in terms of the length also confirms the validity of the model. Covalent type inhibitors were chosen for docking to reduce ambiguity over their binding modes. It is generally accepted that sterically unhindered N-containing heterocycles (e.g. pyridine, imidazole, and, triazole) make a coordinate bond with the heme iron, as seen in the crystal structure of P450 CAM with a bound pyridine derivative 42) . Methylenedioxyphenyl derivatives are also thought to make covalent bonds by attacking the heme iron from a methylene bridge carbene.
14) These N-containing heterocycle and methylene- dioxyphenyl derivatives are useful for elucidating the general features of the active-site pockets of CYPs.
Paclitaxel is hydroxylated by CYP3A4 at the phenyl ring of the C3Ј position. 43) Ten docking modes of paclitaxel offered by Gold were similar to each other. In the docking modes, paclitaxel has an orientation that can account for the metabolite formation (Fig. 5a ). The bulky taxane skeleton was docked in the distal site 2, which is the largest of the three sites in the pocket.
On the other hand, various bound orientations of losartan 
Fig. 3. (a) Distribution of the Amino Acid Residues Reported as Important Sites for Ligand-Binding
Heme is displayed in orange, acidic residues in red, basic residues in blue, polar residues in magenta and hydrophobic residues in yellow. Magenta dot surface indicates the shape of the pocket. ) were generated by Gold. The most reasonable binding mode of losartan, therefore, was explored using the pharmacophore docking program Ph4Dock in MOE. Pharmacophore dock is a new docking methodology, which involves a ligand-based pharmacophore being introduced in an automated docking method. The merit of Ph4Dock is that the binding mode consistent with a predicted ligand-based pharmacophore can be obtained considering structural information of a protein. The pharmacophore used here for Ph4Dock consists of 7 hydrophobic areas, 3 hydrogen bond donor sites, and 2 hydrogen bond donor and acceptor sites (Fig. 6) . In the procedure, the flexibility of side chains around the ligand was considered by energy minimization of the complex. Rank indicates the ranking in orientation candidates obtained by Ph4Dock. U vdw ϩU ele is the sum of interaction energy (van der Waalsϩelectrostatic) calculated by MMFF94s force field. The last five columns are for the orientations consistent with the metabolite formation. Ph4Dock predicted a single binding mode, in which the hydroxy group of losartan forms a hydrogen bond with the side chain of Glu374, which is located at the approach to the distal site 2 (Fig. 5b) . It is reported that losartan and irbesartan exhibit week affinity toward CYP3A4, whereas eprosartan, valsartan, and candesartan have no affinity (Table 2 44) ). The difference of affinity for CYP3A4 may be derived from the existence of a carboxylic acid at the equivalent position to the hydroxy group of losartan. It may be assumed that the minus charge of the carboxylic acid will repel the side chain of the glutamate. In addition to Glu374, two acidic amino acids (Asp214 and Asp217) exist at the approach to the distal site 2. If our analysis about the sartans is correct, introduction of an acidic substituent at an appropriate position could be a good way of solving the CYP3A4 inhibitory problem.
To examine whether bound orientations and binding potency of substrates can be predicted with a reasonable accuracy, pharmacophore docking for typical CYP3A4 substrates was carried out using Ph4Dock, using the procedure described above. As shown in Table 3 , half the top-rank models were consistent with the formation of their metabolites. Interaction energies for the 14 substrates were then plotted against the logarithm of the published apparent K m values (Table 3) . When the top-rank model was adopted for each compound, the correlation was not so good ( Fig. 7a ; the R 2 value is 0.532). On the other hand, by selecting the orientation consistent with each metabolite formation, a moderate correlation was obtained ( Fig. 7b ; the R 2 value is 0.779). It was also found that the electrostatic interaction energy contributes more than the van der Waals energy, especially when saquinavir and colchicine are compared ( Table 3 ). The precise cause could not be determined, but the interaction with the acidic amino acids (e.g. Glu374, Asp214 and Asp217) might be one of the reasons. Although other factors have to be considered to improve the correlation, a combination of Ph4Dock and molecular orbital calculations, which can be used for predicting metabolizable positions, should be extremely useful.
Conclusions
We have constructed a homology model of CYP3A4, the most important isoform of human CYPs for drug-drug interactions. The structure is based on the crystallographic coordinates of mammalian CYP2C5. The relatively large activesite pocket of the model, which is consistent with the broad substrate selectivity of CYP3A4, is divided into three parts (a proximal and two distal sites from the heme). Most of the residues that have been reported to be important for ligandbinding are located in the active site.
Ketoconazole and the methylenedioxyphenyl derivative docked into the model have a length similar to that of the putative pocket. Paclitaxel bound to the model is also complementary to the shape of the pocket and has an orientation that is consistent with the observed metabolite formation. In the binding model of losartan, the hydroxy group is assumed to form a hydrogen bond with the side chain of Glu374, which might be the reason for the lack of affinity of some sartans with carboxylic acid moieties at the equivalent position to the hydroxy group of losartan.
The interaction energies calculated with Ph4Dock show a moderate correlation with the reported K m values. From this result, it is expected that this CYP3A4 model is reliable enough to be used in the design of compounds for removing undesirable CYP3A4 inhibition. 
